Tempest Therapeutics jumps on positive data from liver cancer combo therapy trial

Tempest Therapeutics

11/10/2023 16:27

(Updates)
    ** Drug developer Tempest Therapeutics'  TPST.O  shares jump
more than 11x to $2.95; stock among top pct gainers across U.S.
stock exchanges
    ** Company reports positive updated response data from
early-to-mid-stage stage trial testing its experimental
treatment TPST-1120 in combination for a type of liver cancer
called hepatocellular carcinoma (HCC)
    ** Trial tested TPST-1120 in combination with Roche's
 ROG.S  atezolizumab and bevacizumab in a randomized comparison
vs control arm where atezolizumab and bevacizumab were
administered
    ** Company confirms objective response rate of 30% for
TPST-1120 triplet arm vs 13.3% for control arm
    ** TPST-1120 remains well tolerated, with safety data
comparable between two arms, Tempest says
    ** Roche managed study operations for multicenter trial,
pursuant to clinical collaboration; Tempest retains all product
rights to TPST-1120
    ** Brokerage H.C. Wainwright raises PT on Tempest shares to
$47 from $35

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com))